Idioma:

Clinical implications of the intrinsic molecular subtypes of breast cancer

Prat, Aleix ; Pineda, Estela ; Adamo, Barbara ; Galván, Patricia ; Fernández, Aranzazu ; Gaba, Lydia ; Díez, Marc ; Viladot, Margarita ; Arance, Ana ; Muñoz, Montserrat

Breast (Edinburgh), 2015-11, Vol.24, p.S26-S35 [Periódico revisado por pares]

Netherlands: Elsevier Ltd

Texto completo disponível

Citações Citado por

Enviar para

Título:
Clinical implications of the intrinsic molecular subtypes of breast cancer
Autor: Prat, Aleix ; Pineda, Estela ; Adamo, Barbara ; Galván, Patricia ; Fernández, Aranzazu ; Gaba, Lydia ; Díez, Marc ; Viladot, Margarita ; Arance, Ana ; Muñoz, Montserrat
Assuntos: Antineoplastic Combined Chemotherapy Protocols - therapeutic use ; Breast cancer ; Breast Neoplasms - chemistry ; Breast Neoplasms - classification ; Breast Neoplasms - drug therapy ; Breast Neoplasms - genetics ; Chemotherapy, Adjuvant ; Female ; Gene expression ; Gene Expression Profiling ; Hematology, Oncology and Palliative Medicine ; Humans ; Neoadjuvant Therapy ; PAM50 ; Prognosis ; Receptor, ErbB-2 - analysis ; Receptors, Estrogen - analysis ; Receptors, Progesterone - analysis ; Subtype ; Triple Negative Breast Neoplasms - classification ; Triple Negative Breast Neoplasms - drug therapy ; Triple Negative Breast Neoplasms - genetics
É parte de: Breast (Edinburgh), 2015-11, Vol.24, p.S26-S35
Notas: ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-3
content type line 23
ObjectType-Review-1
Descrição: Abstract Gene-expression profiling has had a considerable impact on our understanding of breast cancer biology. During the last 15 years, 5 intrinsic molecular subtypes of breast cancer (Luminal A, Luminal B, HER2-enriched, Basal-like and Claudin-low) have been identified and intensively studied. In this review, we will focus on the current and future clinical implications of the intrinsic molecular subtypes beyond the current pathological-based classification endorsed by the 2013 St. Gallen Consensus Recommendations. Within hormone receptor-positive and HER2-negative early breast cancer, the Luminal A and B subtypes predict 10-year outcome regardless of systemic treatment administered as well as residual risk of distant recurrence after 5 years of endocrine therapy. Within clinically HER2-positive disease, the 4 main intrinsic subtypes can be identified and dominate the biological and clinical phenotype. From a clinical perspective, patients with HER2+/HER2-enriched disease seem to benefit the most from neoadjuvant trastuzumab, or dual HER2 blockade with trastuzumab/lapatinib, in combination with chemotherapy, and patients with HER2+/Luminal A disease seem to have a relative better outcome compared to the other subtypes. Finally, within triple-negative breast cancer (TNBC), the Basal-like disease predominates (70–80%) and, from a biological perspective, should be considered a cancer-type by itself. Importantly, the distinction between Basal-like versus non-Basal-like within TNBC might predict survival following (neo)adjvuvant multi-agent chemotherapy, bevacizumab benefit in the neoadjuvant setting (CALGB40603), and docetaxel vs. carboplatin benefit in first-line metastatic disease (TNT study). Overall, this data suggests that intrinsic molecular profiling provides clinically relevant information beyond current pathology-based classifications.
Editor: Netherlands: Elsevier Ltd
Idioma: Inglês

Links

View this record in MEDLINE/PubMed

Voltar para lista de resultados

Anterior Resultado 5 Avançar Ir para próxima página

Realização: Logos de Redes Sociais:

Clinical implications of the intrinsic molecular subtypes of breast cancer

Prat, Aleix ; Pineda, Estela ; Adamo, Barbara ; Galván, Patricia ; Fernández, Aranzazu ; Gaba, Lydia ; Díez, Marc ; Viladot, Margarita ; Arance, Ana ; Muñoz, Montserrat

Netherlands: Elsevier Ltd

Buscando em bases de dados remotas. Favor aguardar.